Recent Updates
Recently added Catalysts

COPD Exacerbation: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$122Muniverse median $1.20B
Allocated capital$61M$122M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank284/299crowding rank 284

COPD Exacerbation is uncontested. Connect Biopharma Holdings (CNTB) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Rademikibart in prefilled syringe in phase 2.

There is no public comparable to price it against. CNTB spreads its $122M market cap across 2 indications, so $61M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$61M of allocated capital sits in COPD Exacerbation, ranking it 284th of 299 indications by the money committed to it.

Companies developing drugs for COPD Exacerbation 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CNTBConnect Biopharma HoldingsRademikibart in prefilled syringePhase 21$122MNo2 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why COPD Exacerbation counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. COPD Exacerbation has one competitor and a median of $122M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Childhood-onset Systemic Lupus Erythematosus1 company · $69M · median $276MUncontestedDiffuse Cutaneous Systemic Sclerosis1 company · $51M · median $101MUncontestedAcute Respiratory Distress Syndrome1 company · $136M · median $272MUncontestedPemphigus1 company · $148M · median $590MUncontestedCOPD1 company · $167M · median $333MUncontestedPrevention of Acute Rejection in Renal Transplant1 company · $226M · median $226MUncontestedOsteoarthritis Patients Scheduled for Total Knee Replacement Surgery1 company · $265M · median $1.1BUncontestedIdiopathic Membranous Nephropathy1 company · $279M · median $838MUncontested

COPD Exacerbation pipeline questions

Which biotech companies are developing drugs for COPD Exacerbation?

Connect Biopharma Holdings (CNTB, Rademikibart in prefilled syringe, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in COPD Exacerbation.

How advanced is the COPD Exacerbation pipeline?

Of the 1 clinical-stage programme in COPD Exacerbation, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for COPD Exacerbation?

No. CNTB is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in COPD Exacerbation, which is why the indication is classified as uncontested.

When is the next COPD Exacerbation catalyst?

The next dated catalyst in COPD Exacerbation is CNTB on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map